Search Web Site
Personal tools
front page map

Click on the map for a list of participating countries.

What is the ISCHEMIA Study?
  • An international comparative effectiveness study

  • The purpose of ISCHEMIA is to determine the best way to manage stable ischemic heart disease

  • Patients with moderate or severe ischemia on stress test imaging may be eligible for participation

 If you are a physician and would like more information, please visit the For Physicians section. If you are a patient and would like to learn more about the ISCHEMIA study, please e-mail

Drs. George Dangas, Judith Hochman, and Gregg Stone discuss the ISCHEMIA Trial and why every interventionalist should actively participate.

Why is the ISCHEMIA Study Important?

Ischemic heart disease (IHD) is the leading cause of death and disability worldwide and affects 17,600,000 Americans, resulting in about 450,000 deaths in the United States annually. Globally, 7.2 million deaths are caused by IHD each year.

Medical therapy (medication and lifestyle changes) should always be used to treat IHD. Many doctors routinely use an invasive approach in addition to medical therapy to treat IHD; however, it is not known if this approach is better than medical therapy alone as the initial treatment of patients with stable ischemic heart disease (SIHD). ISCHEMIA is designed to find the answer. Click here to learn more about the ISCHEMIA study.

Study Coordinator Webinar

Join us for our monthly study coordinator webinar the last Thursday of each month! Contact the ISCHEMIA CCC for details.

ISCHEMIA Enrollment Update

Congratulations to our top randomizing sites!

  • Northwick Park Hospital (Middlesex, United Kingdom): Drs. Roxy Senior and Ahmed Elghamaz & SCs Grace Young, Jo Evans, Sothinathan Gurunathan, & Christopher Kinsey  (82)
  • Government Medical College (Calicut, India): Drs. Mangalath Krishnan and Rajesh Nair & SC Jisha Shamshuddin (56)
  • Coronary and Structural Heart Diseases Department, Institute of Cardiology (Warsaw, Poland): Drs. Marcin Demkow and Radek Pracon & SC Olga Chojnacka  (54)
  • Hospital Universitario La Paz (Madrid, Spain): Drs. Jose Luis Lopez Sendon and Raul Moreno & SCs Almudena Castro & Silvia Valbuena (50)
  • Montreal Heart Institute (Montreal, Canada): Drs. Gilbert Gosselin and Patrick Garceau  & SCs Rima Amche & Magalie Corfias  (41)
  • Atlanta V.A. Medical Center (Decatur, USA): Drs. Kreton Mavromatis and Dr. Jason Linefsky & SCs Charlene Brown and Pankaj Manocha (38)
  • Bakulev Scientific Center for Cardiovascular Surgery (Moscow, Russia): Drs. Leo Bockeria & Bagrat Alekyan & SCs Olga Bockeria & Zalina Kudzoeva (37)
  • Centre Hospitalier Regional de Trois-Rivieres (Trois-Rivieres, Canada): Drs. Ariel Diaz and Gilbert Gosselin & SC Isabelle Roy (34)
  • Medical University of Lodz (Lodz, Poland): Drs. Jarozlaw Drozdz, Ryszard Jasewski & Jan Zbigniew Peruga and SCs Bartosz Czariak, Beata Smarzyk & Marta Swiderek (27)
  • Sri Jayadeva Institute of Cardiovascular Sciences and Research (Bangalore, India): Drs. Cholenahally Nanjappa Manjunath, Nagaraj Moorthy, Suryaprakash Narayanappa & SCs Krishna Murthy & Nandita N (27)
  • University Hospital (London, Canada): Drs. Dennis Humen, William Kostuk & Shahar Lavi & SC Sandy Carr (26)
  • Vilnius University Hospital Santariskes Clinic (Vilnius, Lithuania): Drs. Aleksandras Laucevicius & Giedrius Davidavicius & SCs Irina Alitoit, Jelena Celutkiene & Denis Kablucko (26)

As of March 23, there are 1572 participants randomized across Argentina, Australia, Austria, Belgium, Brazil, Canada, China, France, Germany, Hungary, India, Israel, Italy, Japan, Lithuania, Macedonia, Mexico, New Zealand, Poland, Portugal, Russia, Saudi Arabia, Serbia, Singapore, Spain, Sweden, Switzerland, the United Kingdom and the United States.